Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Summary

Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), ...

Description

Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), ...

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source